ArticleBioanalysis2026
Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA.
Article in Bioanalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe traditional immunogenicity paradigm resulting in anti-drug antibody (ADA) and neutralizing antibody (NAb) positive/negative status and ambiguous or imprecise titers may overlook clinically relevant effects of ADA on pharmacokinetics (PK) and pharmacodynamics (PD). Employing risk-based strategies that integrate PK and PD analyses with ADA magnitude using signal-to-noise (S/N) can provide early insight into potential clinical impact of immunogenicity. MATERIALS AND
methodsIn a Phase 1 evaluation of DLX-2323, a humanized single-chain variable fragment (scFv) antibody that binds human IL-1β, ADA-sensitive PK and PD assays were employed to measure DLX-2323 concentration, PD activity, and assess the impact of ADA on PK and PD in healthy participants.
resultsThe presence of pre-existing ADA was observed in one-third of participants and resulted in high variability of DLX-2323 exposure and PD activity. Pre-existing ADA magnitude correlated with a drug-sustaining impact on PK and PD, with lower clearance (CL/F) and volume of distribution (Vd/F) of DLX-2323 relative to increasing ADA signal.
conclusionsBased on the immunogenicity risk assessment, the use of ADA-sensitive free PK and PD assays to measure
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.